Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Sell
42
ITCI Quote, Financials, Valuation and Earnings
Last price:
$94.86
Seasonality move
:
2.9%
Day range:
$86.25 - $98.40
52-week range:
$62.78 - $98.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.58x
P/B ratio:
8.79x
Volume:
4.1M
Avg. volume:
586.4K
1-year change:
40.38%
Market cap:
$10.1B
Revenue:
$462.2M
EPS (TTM):
-$0.87
Analysts' Opinion
-
Consensus RatingIntra-Cellular Therapies has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $103.21, Intra-Cellular Therapies has an estimated upside of 8.8% from its current price of $94.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $87.00 representing 8.3% downside risk from its current price of $94.87.
Fair Value
-
According to the consensus of 10 analysts, Intra-Cellular Therapies has 8.8% upside to fair value with a price target of $103.21 per share.
ITCI vs. S&P 500
-
Over the past 5 trading days, Intra-Cellular Therapies has overperformed the S&P 500 by 14.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Intra-Cellular Therapies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intra-Cellular Therapies has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Intra-Cellular Therapies reported revenues of $175.2M.
Earnings Growth
-
Intra-Cellular Therapies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intra-Cellular Therapies reported earnings per share of -$0.25.
Enterprise value:
9.1B
EV / Invested capital:
--
Price / LTM sales:
15.58x
EV / EBIT:
--
EV / Revenue:
14.77x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-143.88x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$565.5M
Return On Assets:
-8.93%
Net Income Margin (TTM):
-14.1%
Return On Equity:
-10.58%
Return On Invested Capital:
-10.58%
Operating Margin:
-22.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $187.2M | $418.1M | $612.8M | $125.8M | $175.2M | |
| Gross Profit | $171M | $388.3M | $565.5M | $116.7M | $159.9M | |
| Operating Income | -$302.2M | -$172.7M | -$121.6M | -$29.7M | -$38.8M | |
| EBITDA | -$301.6M | -$172.2M | -$121.1M | -$29.6M | -$38.7M | |
| Diluted EPS | -$3.32 | -$1.61 | -$0.87 | -$0.25 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $744.9M | $533.2M | $759.8M | $702.4M | $1.3B | |
| Total Assets | $771.3M | $557M | $782M | $717.7M | $1.3B | |
| Current Liabilities | $38M | $49.9M | $77.4M | $103.1M | $166.1M | |
| Total Liabilities | $61.9M | $70.2M | $96.6M | $117M | $179.6M | |
| Total Equity | $709.4M | $486.8M | $685.4M | $600.7M | $1.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$304.2M | -$161.3M | -$62.2M | -$25.3M | -$26.5M | |
| Cash From Investing | -$127.1M | $108.4M | -$137.8M | -$20.2M | -$209.2M | |
| Cash From Financing | $460.9M | $17M | $564.9M | $2.6M | $6.7M | |
| Free Cash Flow | -$305M | -$161.6M | -$62.9M | -$25.5M | -$27.2M | |
ITCI
Sector
Market Cap
$10.1B
$47.5M
Price % of 52-Week High
96.42%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
40.38%
-34.04%
Beta (5-Year)
0.704
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$84.68
200-day SMA
Buy
Level
$75.72
Bollinger Bands (100)
Buy
Level
74.04 - 85.96
Chaikin Money Flow
Buy
Level
37.2M
20-day SMA
Buy
Level
$84.71
Relative Strength Index (RSI14)
Buy
Level
71.02
ADX Line
Buy
Level
34.57
Williams %R
Neutral
Level
-20.0626
50-day SMA
Buy
Level
$85.48
MACD (12, 26)
Buy
Level
0.52
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
110.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (27.9599)
Buy
CA Score
(Annual)
Level (0.3768)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.5989)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Stock Forecast FAQ
In the current month, ITCI has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ITCI average analyst price target in the past 3 months is $103.21.
-
Where Will Intra-Cellular Therapies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intra-Cellular Therapies share price will rise to $103.21 per share over the next 12 months.
-
What Do Analysts Say About Intra-Cellular Therapies?
Analysts are divided on their view about Intra-Cellular Therapies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intra-Cellular Therapies is a Sell and believe this share price will drop from its current level to $87.00.
-
What Is Intra-Cellular Therapies's Price Target?
The price target for Intra-Cellular Therapies over the next 1-year time period is forecast to be $103.21 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ITCI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intra-Cellular Therapies is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ITCI?
You can purchase shares of Intra-Cellular Therapies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intra-Cellular Therapies shares.
-
What Is The Intra-Cellular Therapies Share Price Today?
Intra-Cellular Therapies was last trading at $94.86 per share. This represents the most recent stock quote for Intra-Cellular Therapies. Yesterday, Intra-Cellular Therapies closed at $94.87 per share.
-
How To Buy Intra-Cellular Therapies Stock Online?
In order to purchase Intra-Cellular Therapies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
